Verici Dx plc (LON:VRCI – Get Free Report)’s share price traded up 4.4% on Thursday . The stock traded as high as GBX 2.48 ($0.03) and last traded at GBX 2.48 ($0.03). 215,225 shares were traded during trading, a decline of 36% from the average session volume of 333,685 shares. The stock had previously closed at GBX 2.38 ($0.03).
Verici Dx Stock Performance
The company has a debt-to-equity ratio of 4.65, a current ratio of 4.54 and a quick ratio of 8.49. The company has a market capitalization of £7.88 million, a price-to-earnings ratio of -162.50 and a beta of 1.59. The stock has a 50-day moving average price of GBX 3.07 and a 200-day moving average price of GBX 5.43.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
See Also
- Five stocks we like better than Verici Dx
- What does consumer price index measure?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Business Services Stocks Investing
- Top 3 ETFs to Hedge Against Inflation in 2025
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
